Opportunities and hurdles in the treatment of BRCA1-related breast cancer
- PMID: 23955079
- DOI: 10.1038/onc.2013.329
Opportunities and hurdles in the treatment of BRCA1-related breast cancer
Abstract
BRCA1 functions as a classical tumor suppressor in breast and ovarian cancer. While the role of BRCA1 in homology-directed repair of DNA double-strand breaks contributes to its tumor suppressive activity, it also renders BRCA1-deficient cells highly sensitive to DNA-damaging agents. Although BRCA1 deficiency is therefore considered to be an attractive therapeutic target, re-activation of BRCA1 by secondary mutations has been shown to cause therapy resistance. In this review, we will assess the role of BRCA1 in both hereditary and sporadic breast cancer and discuss how different functionalities of the BRCA1 protein can contribute to its tumor suppressor function. In addition, we will discuss how this knowledge on BRCA1 function can help to overcome the hurdles encountered in the clinic and improve current treatment strategies for patients with BRCA1-related breast cancer.
Similar articles
-
In brief: BRCA1 and BRCA2.J Pathol. 2013 Aug;230(4):347-9. doi: 10.1002/path.4205. J Pathol. 2013. PMID: 23620175 Review.
-
The role of the BRCA1 tumor suppressor in DNA double-strand break repair.Mol Cancer Res. 2005 Oct;3(10):531-9. doi: 10.1158/1541-7786.MCR-05-0192. Mol Cancer Res. 2005. PMID: 16254187 Review.
-
BRCA1 gene in breast cancer.J Cell Physiol. 2003 Jul;196(1):19-41. doi: 10.1002/jcp.10257. J Cell Physiol. 2003. PMID: 12767038 Review.
-
Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.Breast Cancer Res Treat. 2012 Feb;132(1):87-95. doi: 10.1007/s10549-011-1544-9. Epub 2011 May 7. Breast Cancer Res Treat. 2012. PMID: 21553119
-
p53, BRCA1 and breast Cancer chemoresistance.Adv Exp Med Biol. 2007;608:70-86. doi: 10.1007/978-0-387-74039-3_5. Adv Exp Med Biol. 2007. PMID: 17993233 Review.
Cited by
-
PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors.Breast Cancer Res. 2021 Jan 21;23(1):10. doi: 10.1186/s13058-021-01387-x. Breast Cancer Res. 2021. PMID: 33478572 Free PMC article.
-
Systematic investigation of BRCA1-A, -B, and -C complexes and their functions in DNA damage response and DNA repair.Oncogene. 2024 Aug;43(35):2621-2634. doi: 10.1038/s41388-024-03108-y. Epub 2024 Jul 27. Oncogene. 2024. PMID: 39068216
-
A Novel Mutation-BRCA1 Associated Hereditary Haplotype of Intragenic Markers of BRCA1 Gene in a Family with History of Breast Cancer.Asian Pac J Cancer Prev. 2019 Feb 26;20(2):611-614. doi: 10.31557/APJCP.2019.20.2.611. Asian Pac J Cancer Prev. 2019. PMID: 30806067 Free PMC article.
-
PARP Inhibition by Flavonoids Induced Selective Cell Killing to BRCA2-Deficient Cells.Pharmaceuticals (Basel). 2017 Oct 12;10(4):80. doi: 10.3390/ph10040080. Pharmaceuticals (Basel). 2017. PMID: 29023372 Free PMC article.
-
BBIT20 inhibits homologous DNA repair with disruption of the BRCA1-BARD1 interaction in breast and ovarian cancer.Br J Pharmacol. 2021 Sep;178(18):3627-3647. doi: 10.1111/bph.15506. Epub 2021 Jun 11. Br J Pharmacol. 2021. PMID: 33899955 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous